₹ 0.1 Cr
Volume transacted
4.6 K
stocks traded
Last Updated time: 26 Jul 15:30 PM
Bal Pharma Ltd
NSE: BALPHARMA
DPS
₹ 1
Last updated : FY 2023
The Dividend per Share of Bal Pharma Ltd is ₹ 1 as of 2023 .a1#The Dividend Payout of Bal Pharma Ltd changed from 20.96 % on March 2019 to 25.6 % on March 2023 . This represents a CAGR of 4.08% over 5 years. a1#The Latest Trading Price of Bal Pharma Ltd is ₹ 117.55 as of 26 Jul 15:31 .a1#The Market Cap of Bal Pharma Ltd changed from ₹ 99.92 crore on March 2019 to ₹ 105.01 crore on March 2023 . This represents a CAGR of 1.00% over 5 years. a1#The Revenue of Bal Pharma Ltd changed from ₹ 70.08 crore to ₹ 97.08 crore over 8 quarters. This represents a CAGR of 17.70% a1#The EBITDA of Bal Pharma Ltd changed from ₹ 5.28 crore to ₹ 12.05 crore over 8 quarters. This represents a CAGR of 51.07% a1#The Net Pr of Bal Pharma Ltd changed from ₹ 0.28 crore to ₹ 5.53 crore over 8 quarters. This represents a CAGR of 344.41% a1#
Open Demat Account
Enter your mobile no. to continue
+91
*By signing up you agree to our terms & conditions
50 Years
of Trust & Legacy
₹0 AMC
for First Year
₹0 Brokerage
on Delivery, Intraday, Currency and NSE F&O
Market Cap
₹ 183 Cr
EPS
₹ 4.7
P/E Ratio (TTM) *
24.8
P/B Ratio (TTM) *
2.7
DTE *
2.0
ROE *
10.7
ROCE *
11.5
Dividend Yield *
1.49
DPS *
1
Dividend Payout *
25.6
Ann.Dividend % *
10
* All values are consolidated
Last Updated time: 26 Jul 15:30 PM
* All values are consolidated
Last Updated time: 26 Jul 15:30 PM
Dividend payout refers to the total dividends paid to shareholders relative to the company's earnings. It is a financial measure that determines the percentage of earnings paid out to existing shareholders as dividends. How to calculate Dividend Payout Ratio? The dividend payout ratio formula is as follows: DPR = Dividends paid / Net earnings With the dividend payout ratio, you can understand the company's priorities. It is an important metric that allows you to easily check DPR online.
Period | |
---|---|
Mar '19 | 21 |
Mar '20 | 0 |
Mar '21 | 16 |
Mar '22 | 17 |
Mar '23 | 26 |
* All values are a in %
Dividend Yield is a financial ratio that shows the annual dividend income relative to the market price of a share. It is calculated by dividing the dividend per share by the current market price per share, expressed as a percentage.
* All values are in %
Bal Pharma Ltd
NSE: BALPHARMA
PRICE
₹ 117.55
1.45 (1.25%)
Last updated : 26 Jul 15:31
Strength
2
S
Weakness
2
W
Opportunity
0
O
Threats
0
T
A dividend is paid on common stock when a company has accumulated substantial profits over years, often seen as excess cash that doesn't need immediate use.
A quarterly dividend is paid to preferred stock owners, typically accumulating a fixed amount, and is earned on shares that function more like bonds.
Companies declare interim dividends before final full-year accounts are prepared, specifically in India, during the financial year from April to March of the following year.
A final dividend is issued after the year's accounts have been compiled. Aside from this, the following list highlights the most prevalent sorts of dividends:
Market Cap or market capitalisation refers to metrics that are used to measure a company's size. It is defined as the total market value of a company's outstanding shares of stock. Formula of Market Cap: Market Capital = N * P Here, N for the outstanding shares P refers to the closing price of the company's shares. Types of Companies based on Market Cap: - Small-Cap stocks: Up to 500 Crore - Mid-Cap Stocks: From Rs.500 crore up to Rs.7,000 crore - Large-Cap Stocks: From Rs.7,000 crore up to Rs.20,000 crore
Period | |
---|---|
Mar '19 | 100 |
Mar '20 | 46 |
Mar '21 | 80 |
Mar '22 | 160 |
Mar '23 | 105 |
* All values are a in ₹crore
Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services. Types of Revenue: 1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered. 2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees. Formula for Revenue: The formula for calculating revenue is based on two goods & services: For goods: Revenue = Avg unit price x Number of Units sold For services: Revenue = Avg unit price x Number of Customers served.
Period | |
---|---|
Jun '22 | 70 |
Sep '22 | 75 |
Dec '22 | 77 |
Mar '23 | 83 |
Jun '23 | 71 |
Sep '23 | 93 |
Dec '23 | 82 |
Mar '24 | 97 |
* All values are a in ₹crore
PBIDT stands for Profit Before Interest, Depreciation, and Taxes. It is a financial metric that measures a company's profitability before accounting for interest expenses, depreciation of assets, and taxes. Formula to calculate PBIDT: PBIDT = Net Income + Interest + Depreciation + Taxes or PBIDT = Operating Income + Depreciation + Taxes PBIDT vs EBITDA vs EBIT vs EBT: Here is a brief explanation of the differences: - PBIDT (Profit Before Interest, Depreciation, and Taxes) includes taxes in its calculation, unlike EBITDA. - EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) excludes taxes and interest, focusing on operational performance. - EBIT (Earnings Before Interest and Taxes) excludes interest and taxes, providing a measure of core operational profitability. - EBT (Earnings Before Taxes) includes all operating income but does not account for interest expenses. Conclusion: PBIDT, similar to EBITDA, is a measure of operational profitability but includes taxes in its calculation.
Period | |
---|---|
Jun '22 | 5 |
Sep '22 | 6 |
Dec '22 | 7 |
Mar '23 | 8 |
Jun '23 | 7 |
Sep '23 | 8 |
Dec '23 | 8 |
Mar '24 | 12 |
* All values are a in ₹crore
Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions. Net Profit formula is expressed as: Net Profit = Total Revenue - Total Expense Net Profit Margin Ratio: Net Profit Margin Ratio = Net Profit / Total Revenue
Period | |
---|---|
Jun '22 | 0 |
Sep '22 | 0 |
Dec '22 | 1 |
Mar '23 | 2 |
Jun '23 | 0 |
Sep '23 | 1 |
Dec '23 | 1 |
Mar '24 | 6 |
* All values are a in ₹crore
Bal Pharma Ltd (BPL), a member of the Mcro Laboratories Group, was incorporated as a private limited company in May '87. In Mar.'90, BPL took over a pharmaceutical products manufacturing unit located in Bangalore through the Karnataka State Finance Corporation for a consideration of Rs 25.18 lac following which, BPL commenced manufacturing formulations. BPL manufactures and markets pharmaceutical formulations -- paracetamol, aluminium hydroxide, povidone iodine, alprazolam, gliclazide, griseofulvin, lactobacillus, rifampicin, piroxicam amoxycillin, etc. The company promotes its products through the common sales force of the group but proposes to induct its own soon. It came out with a public issue in Feb.'95 for manufacture of bulk drugs and expansion of pharmaceutical formulations. During 1997-98, the formalities of takeover of the unit from Lakme Limited have been completed and effective from 23rd July, 1997 the unit has become a division of Bal Pharma Limited. The company's product range has been expanded with the introduction of AZIWIN, CAFIMOL & CORTIDERM. The company has added further product range Zanovid, Aziwin, Dry Syrup, Meloxi, Ocium - M, Progit - MPS in its ethical division during 1999-2000. As part of the expansion of the product range, the company has introduced Cardiac Specialities Products. To market these products, a new division named 'SERVETUS' has started functioning during 2001. New products like Amiloride,Benzydamine and Ebastine were rolled into the market during 2002. The commercial production of Formulation Plant in Uttarakhand started from 1st January, 2009. The Company floated Lifezen Healthcare Pvt Ltd during the year 2014-15 as its subsidiary. It ventured into heath care sector through its subsidiary i.e. Balance Clinics LLP. In 2016-17, it commenced its project on construction of an fully integrated API unit with an annual production capacity of 270 metric tonnes of assorted API products including Gliclazide, Ebastine, Amiloride HCL, Benzydamine HCL, Pregablin etc, located at Gauribidanur near Bangalore with an estimated investment of Rs 45 Crores. In 2017-18, the Company acquired 100% stake and management control of Golden Drugs Private Ltd, an Udaipur, Rajasthan involved in the manufacture of bulk drugs and intermediates costing Rs 14 Crores. It earmarked Rs. 36 Cr. for setting up of an bulk drug's manufacturing unit at Yadgir District , Karnataka in year 2022-23. It launched Sitagliptin (a DPP-4 Inhibitor) in the plain form, and as a combination with Metformin under the brand names SITABEND & SITABEND-M, respectively in 2023.
Board of Bal Pharma recommends final dividend
Bal Pharma announced that the Board of Directors of the Company at its meeting held on 28 ...
Read more
29 May 202409:43
Bal Pharma Ltd leads gainers in 'B' group
Amines & Plasticizers Ltd, Jet Freight Logistics Ltd, Arrow Greentech Ltd and Emkay Global...
Read more
29 May 202412:15
Bal Pharma hits the roof after Q4 PAT surges to Rs 5 cr
Revenue from operations jumped 14.76% YoY to Rs 94.62 crore in Q4 FY24. Profit before tax ...
Read more
29 May 202414:47
Bal Pharma declare Quarterly Result
Bal Pharma will hold a meeting of the Board of Directors of the Company on 28 May 2024. Po...
Read more
30 Apr 202412:51
Bal Pharma to table results
Bal Pharma will hold a meeting of the Board of Directors of the Company on 12 February 202...
Read more
25 Jan 202417:14
Bal Pharma to conduct EGM
Bal Pharma announced that an Extra Ordinary General Meeting (EGM) of the Company will be h...
Read more
21 Nov 202310:51
FAQs for dividends of Bal Pharma Ltd
What is the current market price of Bal Pharma Ltd Ltd as of July 26, 2024?
What dividend did Bal Pharma Ltd declare in the last fiscal year?
What is the most recent dividend declared by Bal Pharma Ltd?
How many times has Bal Pharma Ltd declared dividends in the current fiscal year
How many times did Bal Pharma Ltd declare dividends in the previous fiscal year?
Unlimited trading at just
Rs. 199